生物技术公司Chimeric Therapeutics Ltd(ASX: CHM)宣布,将把其独家授权的氯毒素嵌合抗原受体T细胞疗法资产归还给希望之城医疗中心。该疗法资产此前由公司通过独家授权协议获得,现决定终止授权安排并返还相关权益。
生物技术公司Chimeric Therapeutics Ltd(ASX: CHM)宣布,将把其独家授权的氯毒素嵌合抗原受体T细胞疗法资产归还给希望之城医疗中心。该疗法资产此前由公司通过独家授权协议获得,现决定终止授权安排并返还相关权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.